help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, R. D.
Right arrow Articles by Shalet, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, R. D.
Right arrow Articles by Shalet, S. M.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 1 129-135
Copyright © 2002 by The Endocrine Society


Endocrine Care

GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life

R. D. Murray, K. H. Darzy, H. K. Gleeson and S. M. Shalet

Department of Endocrinology, Christie Hospital, Manchester, M20 4BX, United Kingdom

Address all correspondence and requests for reprints to: Prof. S. M. Shalet, Department of Endocrinology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, United Kingdom.

Childhood survivors of cancer are prone to a number of adverse sequelae related to the therapeutic interventions undertaken to achieve remission. The endocrine system is frequently affected; hypothalamo-pituitary dysfunction, in particular GH deficiency, is common after cranial irradiation. It is unclear to what extent GH deficiency contributes to the abnormalities observed in adult survivors of childhood cancer, and whether GH replacement reverses these anomalies. We compared 27 GH-deficient survivors of childhood cancer with 27 adult age- and sex-matched controls and went on to replace GH in the patient group to determine whether GH resulted in improvements of the baseline abnormalities.

The GH-deficient survivors of childhood cancer had an adverse lipid profile (total cholesterol, 5.4 vs. 4.6 mM, P = 0.004; high-density lipoprotein cholesterol, 1.05 vs. 1.6 mM, P < 0.001; and triglycerides, 1.3 vs. 1.0 mM, P < 0.001) and were osteopenic (lumbar spine z-score, -1.53 vs. -0.31 SD score, P < 0.001; femoral neck z-score, -1.23 vs. -0.27 SD score, P = 0.02); additionally, the female subgroup had an increased percentage body fat (43.6 vs. 32.8%, P = 0.016). In keeping with the selection criterion, quality of life in the patient cohort, relative to the healthy controls, was severely impaired [adult GH-deficiency assessment (AGHDA), 15.5 (range, 8–25) vs. 1 (range, 0–19), P < 0.0001; psychological general well-being schedule, 67.5 (range, 18–86) vs. 89.0 (range, 51–104), P < 0.0001].

After 12 months of GH replacement, small (but significant) improvements were observed in body composition in the male subgroup (waist-hip ratio, 0.871 vs. 0.863, P < 0.05); and in the female cohort, total cholesterol (6.0 vs. 5.2 mM, P = 0.01) and triglyceride (2.1 vs. 1.4 mM, P = 0.01) levels fell. Bone mineral density improved in only one of the four sites studied (ultradistal radius, -1.21 vs. -1.09, P = 0.048) after a median duration of GH therapy of 18 months. Quality of life improved dramatically by 3 months (AGHDA, 15.5 vs. 10.0, P < 0.001), and the improvement was maintained at 12 months (AGHDA, 15.5 vs. 9.0, P < 0.001). Importantly, there was no clinical suggestion of tumor recurrence during the 12 months of GH replacement.

The minor improvements observed in body composition, the lipid profile, and bone mineral density in GH-deficient adult survivors of childhood cancer after 12–18 months of physiological GH replacement suggest that GH deficiency may not be the major etiological factor in their pathogenesis; the converse seems to be true for the quality of life status of these individuals. We propose that, as in patients with hypopituitarism caused by pituitary disease, the main indication for GH replacement in GH-deficient survivors of childhood cancer should be severe impairment of quality of life.

Abbreviations: AGHDA, Adult GH-deficiency assessment; ALL, acute lymphoblastic leukemia; BMD, bone mineral density; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; HbA1C, hemoglobin-A1C; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PGWB, psychological general well-being schedule; SDS, SD score; TC, total cholesterol; TG, triglyceride; WHR, waist to hip ratio.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
D Maiter, R Abs, G Johannsson, M Scanlon, P J Jonsson, P Wilton, and M Koltowska-Haggstrom
Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.
Eur. J. Endocrinol., August 1, 2006; 155(2): 253 - 260.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Follin, U. Thilen, B. Ahren, and E. M. Erfurth
Improvement in Cardiac Systolic Function and Reduced Prevalence of Metabolic Syndrome after Two Years of Growth Hormone (GH) Treatment in GH-Deficient Adult Survivors of Childhood-Onset Acute Lymphoblastic Leukemia
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1872 - 1875.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. E. Lipshultz, S. A. Vlach, S. R. Lipsitz, S. E. Sallan, M. L. Schwartz, and S. D. Colan
Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines
Pediatrics, June 1, 2005; 115(6): 1613 - 1622.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Mukherjee, S. Tolhurst-Cleaver, W. D. J. Ryder, L. Smethurst, and S. M. Shalet
The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1542 - 1549.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H K Gleeson and S M Shalet
The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours
Endocr. Relat. Cancer, December 1, 2004; 11(4): 589 - 602.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. K. Gleeson, R. Stoeter, A. L. Ogilvy-Stuart, H. R. Gattamaneni, B. M. Brennan, and S. M. Shalet
Improvements in Final Height Over 25 Years in Growth Hormone (GH)-Deficient Childhood Survivors of Brain Tumors Receiving GH Replacement
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3682 - 3689.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. Misra, L. A Soyka, K. K Miller, S. Grinspoon, L. L Levitsky, and A. Klibanski
Regional body composition in adolescents with anorexia nervosa and changes with weight recovery
Am. J. Clinical Nutrition, June 1, 2003; 77(6): 1361 - 1367.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society